Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIMic: FMT and Immunotherapy in Melanoma
NCT03772899Phase 1Active, not recruiting
- Start
- Mar 2019
- Primary completion
- Sep 2021
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of allogeneic fecal microbiota in melanoma. Primary endpoint: Safety of combining FMT with immunotherapy at 60 months. Started Mar 2019; status: active, not recruiting.
02
Drugs
allogeneic fecal microbiota
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03772899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03772899.